HK Stock Market Move | InnoCare Pharma (09969) rose more than 5% during trading. The study of tanshinone monoclonal antibody combination therapy for the treatment of newly diagnosed stage III DLBCL will be released at the EHA Annual Meeting.

InncoCare Pharma (09969) rose more than 5% in midday trading, and as of the time of this report, it rose 3.29% to 10.69 Hong Kong dollars, with a turnover of 43.0489 million Hong Kong dollars. On the news front, on June 18, according to a message from InnoCare Pharma's official WeChat account, the company announced that at the highest-level plenary session of the 2026 European Hematology Association (EHA) Annual Congress, the global Phase III frontMIND study results of the combination therapy of Tanximab-monoclonal antibody were presented in oral form. The results showed that compared to the existing first-line standard R-CHOP therapy, the study results of the Tanximab-monoclonal antibody combined with lenalidomide and R-CHOP therapy (Tafa-Len-R-CHOP) demonstrated a significant improvement in progression-free survival (PFS), with significant statistical significance and clinical value. It is expected to provide a new first-line standard treatment regimen for high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) patients.